Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. demonstrates a robust financial outlook, with a reported $483 million in combined revenue, reflecting an 18% year-over-year increase, and management projecting peak sales exceeding $1 billion by 2029. The company is actively enhancing the prescribing depth and breadth of its products, with notable growth seen in the XPHOZAH segment, particularly a 41% increase in non-Medicare prescriptions in 2025, driven by strategic investments in patient assistance and sales initiatives. Furthermore, Ardelyx's ongoing Phase 3 trial (ACCEL) for IBSRELA aims to expand its market reach by enrolling patients with chronic idiopathic constipation, with results anticipated in the latter half of 2026 and 2027, suggesting continued potential for revenue growth.

Bears say

Ardelyx Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly pertaining to its IBSRELA product's expected performance, with anticipated revenue reflecting an 18% quarter-over-quarter decline in 1Q26 despite a total forecast of $422 million for FY26. This projection is coupled with a costly monthly price point of approximately $2,300 and decreasing gross-to-net revenue adjustments, which signal potential weaknesses in market penetration and pricing resilience. Additionally, the company's reported net loss of $0.4 million in 4Q25 and low adherence rates among patients utilizing phosphate binders highlight underlying operational and commercial risks that could hinder its financial stability and growth prospects.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.